Fig. 5From: TMEFF2 promoter hypermethylation is an unfavorable prognostic marker in gliomasPrognostic value of TMEFF2 methylation in primary gliomas in TCGA dataset. a Kaplan-Meier curve for OS (month) in patients with low levels of TMEFF2 methylation (n = 519) versus high levels of TMEFF2 methylation (n = 137) in primary glioma. b Kaplan-Meier curve for OS (month) in patients with low levels of TMEFF2 mRNA expression (n = 164) versus high levels of mRNA expression (n = 501) in primary glioma. c OS (month) for four subgroups of primary glioma patients stratified by combinations of both factors: patients with mutant IDH1 and low levels of TMEFF2 methylation (IDH1.MUT-TMEFF2_Methylation.Low), patients with mutant IDH1 and high levels of TMEFF2 methylation (IDH1.MUT-TMEFF2_Methylation.High), patients with wild-type IDH1 and low levels of TMEFF2 methylation (IDH1.WT-TMEFF2_Methylation.Low), and patients with wild-type IDH1 and high levels of TMEFF2 methylation (IDH1.WT-TMEFF2_Methylation.High)Back to article page